Ortho Clinical Diagnostic (NASDAQ: OCDX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.200 | 0.230 | 0.0300 | ||||
REV | 508.210M | 500.100M | -8.110M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ortho Clinical Diagnostic (NASDAQ: OCDX) through any online brokerage.
Other companies in Ortho Clinical Diagnostic’s space includes: Masimo (NASDAQ:MASI), Envista Holdings (NYSE:NVST), Inari Medical (NASDAQ:NARI), Smith & Nephew (NYSE:SNN) and NovoCure (NASDAQ:NVCR).
The latest price target for Ortho Clinical Diagnostic (NASDAQ: OCDX) was reported by Morgan Stanley on Friday, May 6, 2022. The analyst firm set a price target for 18.19 expecting OCDX to rise to within 12 months (a possible 2.31% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Ortho Clinical Diagnostic (NASDAQ: OCDX) is $17.78 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Ortho Clinical Diagnostic.
Ortho Clinical Diagnostic’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Ortho Clinical Diagnostic.
Ortho Clinical Diagnostic is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.